Namenda®
Memantine
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$500+ (brand Namenda XR historical)
With Insurance
$10–30 (generic)
The Short Version
Evidence summary
Namenda (Memantine) is a NMDA Receptor Antagonist prescribed for Moderate to severe Alzheimer's disease and Often combined with cholinesterase inhibitors (donepezil). FDA-approved in October 2003.
The most commonly reported side effects are Dizziness (7%), Headache (6%), Confusion (6%). Rise slowly from seated/lying positions; usually improves with continued use
Review the funding details in the evidence section below.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$55
$20 w/ insurance
without insurance
Annual
$660
$240 w/ insurance
without insurance
10 Years
$6.6K
$2.4K w/ insurance
without insurance
30 Years
$19.8K
$7.2K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. Physical Exercise (Aerobic + Resistance) — Regular exercise associated with 28–45% reduced dementia risk; in MCI patients, structured exercise programs show cognitive improvements comparable to medication effect sizes.
The average American retiree spends $165,000 on healthcare over their lifetime (Fidelity, 2024). Informed choices today compound over decades.
CMS MAHA ELEVATE
This medication has lifestyle alternatives supported by evidence
See how EvidentMeds supports the CMS MAHA ELEVATE program for clinicians
Quick Answers
Now what?
You've read the evidence. Here are your next steps.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Neuroprotection Beyond Medication: Addressing the Modifiable Drivers of Dementia
Memantine modulates glutamate signaling to reduce excitotoxicity — but it does not address the upstream causes of neurodegeneration. Insulin resistance, sedentary behavior, social isolation, poor sleep, and chronic inflammation are all modifiable risk factors that collectively account for an estimated 40% of dementia cases (Lancet Commission, 2020). No current medication addresses these factors.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Physical Exercise (Aerobic + Resistance)
Exercise is the single most evidence-supported modifiable factor for dementia prevention — it increases BDNF, improves vascular health, and reduces neuroinflammation simultaneously
Regular exercise associated with 28–45% reduced dementia risk; in MCI patients, structured exercise programs show cognitive improvements comparable to medication effect sizes.
Social Engagement & Cognitive Stimulation
Social isolation is an independent dementia risk factor equal to physical inactivity; structured cognitive stimulation is NICE-recommended for all dementia stages
Cognitive Stimulation Therapy (CST) shows cognitive benefits equivalent to cholinesterase inhibitors in RCTs, with additional quality-of-life improvements and zero side effects.
Mediterranean / MIND Diet
Anti-inflammatory dietary pattern rich in polyphenols, omega-3s, and leafy greens — targets neuroinflammation at its dietary source
MIND diet associated with 53% reduced AD risk with high adherence; even moderate adherence showed 35% risk reduction. Equivalent to 7.5 years of cognitive aging.
Sleep Quality Optimization
Deep sleep is when the glymphatic system clears amyloid-beta — chronic sleep disruption accelerates plaque accumulation
Sleep disorders increase AD risk 1.5–2×; treating sleep apnea with CPAP has been shown to slow cognitive decline in MCI patients.
Key Studies
Global Prescribing & Pricing
Widely prescribed globally for moderate-severe AD, though benefit size remains debated
United States
$30–80 (generic)/mo
Prescribed across all AD stages despite strongest evidence in moderate-severe only
No requirement for non-pharmacological interventions; frequently added to donepezil without reassessing benefit
Most plans cover generic; brand Namenda XR has restrictions
United Kingdom
~$5–15/mo
NICE recommends only for moderate-severe AD or if cholinesterase inhibitors not tolerated
Specialist initiation; regular reassessment of continued benefit required
NHS covered for moderate-severe AD
Germany
~$10–25/mo
IQWiG found no additional benefit when added to donepezil
GBA restricted to moderate-severe; combination therapy benefit questioned
GKV covered with restrictions
Australia
~$15–30/mo
PBAC listing for moderate-severe AD
Requires cognitive assessment scores within specified range; treatment reviews every 6 months
PBS covered with criteria
Memantine's cost as a generic is modest, but the clinical benefit debate is real. Germany's IQWiG found no proven additional benefit when combining memantine with donepezil — yet this combination is standard practice in the US. The question isn't whether patients can afford it, but whether prescribing it reflexively distracts from investing in non-pharmacological approaches that may matter more.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
All pivotal memantine trials were funded by Forest Laboratories (later acquired by Allergan). Forest Labs was fined $313 million in 2010 for illegal off-label marketing of several drugs, including promoting Namenda for mild AD before it had evidence for that indication. When the patent was expiring, Forest/Allergan attempted a forced-switch scheme — discontinuing the IR tablet to push patients to the extended-release version before generics could launch. NY Attorney General sued and won an injunction blocking this practice.
Declared Conflicts of Interest
Forest Labs' marketing repeatedly overstated memantine's benefits. The drug shows modest improvement in moderate-severe AD but minimal benefit in mild AD. Despite this, it was heavily promoted and prescribed across all stages. The Namenda-to-Namenda XR forced-switch was described by the NY AG as "putting profits over patients" and became a textbook case of pharmaceutical product-hopping.
Key Efficacy Results
Small but statistically significant benefit in moderate-to-severe AD (SIB improvement ~3 points); less convincing evidence in mild AD; modest benefit in agitation/behavioral symptoms
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Memantine. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Memantine in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| Reisberg 2003 (Moderate-Severe AD) | PMID:12672860 | |
| Tariot 2004 (Memantine + Donepezil) | PMID:15258586 | |
| Cochrane Review: Memantine | PMID:17341234 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Dizziness
7%Rise slowly from seated/lying positions; usually improves with continued use
Headache
6%Usually mild and transient; acetaminophen safe for relief
Constipation
5%Increase fiber and fluid intake; important to monitor in elderly patients
Confusion
6%Paradoxical — a drug for dementia can worsen confusion. Report any increase to prescriber.
Hypertension
4%Monitor blood pressure regularly; especially if already on antihypertensives
Serious Adverse Effects
- • Hallucinations — NMDA antagonism can cause visual or auditory hallucinations, especially at higher doses
- • Severe allergic reactions (rare) — rash, swelling, difficulty breathing
- • Stevens-Johnson syndrome — very rare but life-threatening skin reaction reported
- • Seizures — though rare, NMDA modulation can affect seizure threshold
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Hallucinations — NMDA antagonism can cause visual or auditory hallucinations, especially at higher doses
- Severe allergic reactions (rare) — rash, swelling, difficulty breathing
- Stevens-Johnson syndrome — very rare but life-threatening skin reaction reported
- Seizures — though rare, NMDA modulation can affect seizure threshold
- Increased agitation or aggression
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
No adequate human studies. Not typically relevant since Alzheimer's onset is post-reproductive age.
Unknown excretion in breast milk. Clinically not relevant for typical patient population.
Memantine is not indicated for pediatric use. Some off-label research in autism spectrum disorder — results inconclusive.
Most patients are elderly. Monitor for dizziness/falls, confusion worsening, and constipation. Start low (5mg) and titrate slowly over 3+ weeks.
Reduce dose to 5mg twice daily for moderate impairment (CrCl 5-29). Avoid in severe renal impairment.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Memantine does not cause physical dependence, but abrupt discontinuation may lead to noticeable cognitive or behavioral worsening within weeks. Gradual tapering is generally recommended.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Discuss with prescriber — stopping may cause noticeable cognitive decline
- ·Typical taper: reduce by 5mg every 1–2 weeks
- ·For extended-release (28mg), switch to IR formulation for taper if possible
- ·Monitor for behavioral changes, agitation, or increased confusion for 4–6 weeks after stopping
Warning Symptoms — Contact Your Doctor If You Experience:
- Increased agitation or aggression
- Rapid cognitive decline
- New hallucinations
- Sleep disruption
- Increased confusion
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Is the evidence strong enough for my stage of dementia to justify adding memantine?
- 2.Am I already on donepezil — does adding memantine provide a proven additional benefit?
- 3.How will we measure whether this medication is actually helping?
- 4.What non-drug approaches should we be doing alongside or instead of this?
- 5.If there's no measurable improvement in 3–6 months, should we stop?
Lab Tests to Request
- MMSE or MoCA baseline and every 6 months
- Renal function (memantine is renally cleared)
- Blood pressure monitoring
- Comprehensive medication review
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Namenda®
- What is Namenda® used for?
- Namenda® (Memantine) is a NMDA Receptor Antagonist manufactured by Forest Laboratories / Allergan (now generic). FDA-approved indications include: Moderate to severe Alzheimer's disease; Often combined with cholinesterase inhibitors (donepezil).
- What are the common side effects of Namenda®?
- Common side effects of Namenda® include: Dizziness (7%); Headache (6%); Constipation (5%); Confusion (6%); Hypertension (4%).
- How much does Namenda® cost?
- Namenda® list price is approximately $500+ (brand Namenda XR historical). With insurance it typically costs $10–30 (generic); without insurance approximately $30–80 (generic).
- Who funded the clinical trials for Namenda®?
- All pivotal memantine trials were funded by Forest Laboratories (later acquired by Allergan). Forest Labs was fined $313 million in 2010 for illegal off-label marketing of several drugs, including promoting Namenda for mild AD before it had evidence for that indication. When the patent was expiring, Forest/Allergan attempted a forced-switch scheme — discontinuing the IR tablet to push patients to the extended-release version before generics could launch. NY Attorney General sued and won an injunction blocking this practice.
- How strong is the clinical evidence for Namenda®?
- Key studies: Reisberg 2003 (moderate-severe AD), MEM-MD-02 (combination with donepezil), Forest Laboratories trials. Small but statistically significant benefit in moderate-to-severe AD (SIB improvement ~3 points); less convincing evidence in mild AD; modest benefit in agitation/behavioral symptoms Potential conflicts of interest: Forest Labs' marketing repeatedly overstated memantine's benefits. The drug shows modest improvement in moderate-severe AD but minimal benefit in mild AD. Despite this, it was heavily promoted and pre.
- Are there non-drug alternatives to Namenda®?
- Memantine modulates glutamate signaling to reduce excitotoxicity — but it does not address the upstream causes of neurodegeneration. Insulin resistance, sedentary behavior, social isolation, poor sleep, and chronic inflammation are all modifiable risk factors that collectively account for an estimat See the Alternatives tab for full details.
Get notified when we update Namenda®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.